U.S. Stock Night Market Movements

Regencell Bioscience rose 3.18% in the night market. Based on recent important news:

1. On June 17, Regencell Bioscience conducted a stock split, expanding the number of circulating shares, attracting retail investors and driving the stock price up sharply.

2. On June 16, trading began after the stock split, and the stock price continued to rise.

3. On June 18, analysts stated that the surge in stock price was seen as driven by speculation, with a very low proportion of circulating shares leading to significant price volatility.

Stocks with High Trading Volume in the Industry

Eli Lilly fell 0.14% in the night market, with a trading volume of 246,400. Based on recent important news:

1. On July 23, MarketBeat reported that Eli Lilly was not included in the list of five stocks recommended by top analysts, leading to a decline in investor confidence and a 0.14% drop in stock price.

2. On July 22, analysts pointed out that Eli Lilly's price-to-earnings ratio is higher than the industry average, which may affect investors' perception of its valuation.

3. On July 21, analysts' optimistic expectations for Eli Lilly's future drug trials failed to boost the stock price.

Pfizer rose 0.04% in the night market, with a trading volume of 186,500. Based on recent important news:

1. On July 23, analysts maintained a hold rating on Pfizer, believing that five other stocks have more investment value, leading to fluctuations in Pfizer's stock price.

2. On July 22, the position of Chinese pharmaceutical companies in global drug development has improved, increasing the demand for Chinese pharmaceutical companies from multinational pharmaceutical companies, affecting Pfizer's market competition.

3. On July 21, Pfizer and Bristol Myers Squibb launched new purchase options, which may affect its market share.

Novo Nordisk rose 0.07% in the night market, with a trading volume of $132,200. Based on recent important news:

1. On July 22, Novo Nordisk announced that its drug semaglutide was approved for a new indication in China, driving the stock price up.

2. On July 21, Novo Nordisk signed a memorandum of cooperation with Ark to establish a new health management ecosystem, enhancing market confidence.

3. On July 21, analysts predicted that Novo Nordisk would maintain market leadership in the coming years, raising the target price and boosting investor sentiment